JAK2 and myeloproliferative disorder: The prognostic irrelevance of molecular abnormalities such as ASXL1 (P = 0.9), SF3B1 (P = 0.4), or JAK2 V617F (P = 0.8) persisted even in MDS/MPN-RS-T patients with a normal karyotype (n = 61).